Henry Schein, Inc. (NASDAQ:HSIC – Free Report) – Leerink Partnrs lowered their FY2024 earnings estimates for shares of Henry Schein in a note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings per share of $4.74 for the year, down from their previous estimate of $4.81. The consensus estimate for Henry Schein’s current full-year earnings is $4.78 per share. Leerink Partnrs also issued estimates for Henry Schein’s Q4 2024 earnings at $1.19 EPS, Q1 2025 earnings at $1.19 EPS, Q2 2025 earnings at $1.24 EPS, Q3 2025 earnings at $1.25 EPS, Q4 2025 earnings at $1.32 EPS, FY2025 earnings at $5.00 EPS, FY2026 earnings at $5.57 EPS and FY2027 earnings at $6.19 EPS.
Henry Schein (NASDAQ:HSIC – Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of $1.17 by $0.05. The firm had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.24 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The business’s quarterly revenue was up .4% on a year-over-year basis. During the same period last year, the company posted $1.32 EPS.
Henry Schein Stock Performance
Shares of HSIC stock opened at $79.87 on Thursday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The company has a market capitalization of $9.96 billion, a P/E ratio of 32.87, a price-to-earnings-growth ratio of 2.04 and a beta of 0.89. The company’s 50 day moving average price is $73.19 and its two-hundred day moving average price is $71.27. Henry Schein has a 52 week low of $63.67 and a 52 week high of $82.63.
Institutional Trading of Henry Schein
Several institutional investors have recently added to or reduced their stakes in HSIC. FMR LLC boosted its holdings in shares of Henry Schein by 7.8% during the 3rd quarter. FMR LLC now owns 3,280,890 shares of the company’s stock worth $239,177,000 after buying an additional 237,888 shares in the last quarter. Southpoint Capital Advisors LP boosted its holdings in shares of Henry Schein by 30.0% during the 3rd quarter. Southpoint Capital Advisors LP now owns 2,600,000 shares of the company’s stock worth $189,540,000 after buying an additional 600,000 shares in the last quarter. Nuance Investments LLC boosted its holdings in shares of Henry Schein by 22.3% during the 3rd quarter. Nuance Investments LLC now owns 2,278,081 shares of the company’s stock worth $166,072,000 after buying an additional 414,748 shares in the last quarter. Clarkston Capital Partners LLC boosted its holdings in shares of Henry Schein by 5.4% during the 3rd quarter. Clarkston Capital Partners LLC now owns 1,397,805 shares of the company’s stock worth $101,900,000 after buying an additional 71,560 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Henry Schein by 0.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,175,061 shares of the company’s stock worth $85,662,000 after buying an additional 6,184 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.
Insider Activity
In other news, COO Michael S. Ettinger sold 12,240 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $75.00, for a total value of $918,000.00. Following the completion of the transaction, the chief operating officer now owns 87,706 shares of the company’s stock, valued at $6,577,950. This represents a 12.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 1.14% of the stock is currently owned by insiders.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
See Also
- Five stocks we like better than Henry Schein
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- As China Tightens Rare Earth Exports, These 3 Stocks Are in Focus
- Investing in the High PE Growth Stocks
- Rebuilding the Empire: Can Dollar General Rally in 2025?
- What Investors Need to Know About Upcoming IPOs
- Coinbase Gains Momentum on App Store—What It Means for the Stock
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.